Evidence map›Paper›PMID 39914492›Full record

ArticleTransplantation and cellular therapy2025

Bodyweight and Absolute Lymphocyte Count-Based Dosing of Rabbit Anti-thymocyte Globulin Results in Early CD4

Daniel Drozdov, Jessica Kandil, Susie E Long, Connor V Demorest, Qing Cao, Troy C Lund, Ashish O Gupta, Jaap Jan Boelens, Paul J Orchard

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daniel DrozdovDivision of Blood and Marrow Transplantation and Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota; Division of Stem Cell Transplantation and Cellular Therapies and Children's Research Center, University Children's Hospital Zürich, Zürich, Switzerland; Division of Pediatric Hematology Oncology, Children's Hospital, Kantonsspital Aarau, Aarau, Switzerland. Electronic address: daniel.drozdov@bluewin.ch.
Jessica KandilDivision of Stem Cell Transplantation and Cellular Therapies and Children's Research Center, University Children's Hospital Zürich, Zürich, Switzerland; University of Zürich, Zürich, Switzerland.
Susie E LongAcute Care Pharmacy Services, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota.
Connor V DemorestBiostatistics Core at Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota; Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota.
Qing CaoBiostatistics Core at Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota; Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota.
Troy C LundDivision of Blood and Marrow Transplantation and Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
Ashish O GuptaDivision of Blood and Marrow Transplantation and Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
Jaap Jan BoelensStem Cell Transplantation and Cellular Therapies, Memorial Sloan Kettering Cancer Center, New York, New York.
Paul J OrchardDivision of Blood and Marrow Transplantation and Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundRabbit anti-thymocyte globulin (rATG) decreases the risk of graft failure and graft-versus-host disease (GVHD) in a setting of allogenic hematopoietic cell transplantation (HCT) but has highly variable pharmacokinetics. Recently, it was shown that a dosing nomogram based on recipient bodyweight and absolute lymphocyte count reduced rATG overexposure, which led to faster immune reconstitution. The aim of this study is to evaluate the feasibility and benefits of using an rATG dosing nomogram to achieve early CD4

methodsThe rATG dosing nomogram in pediatric patients with IEM receiving an umbilical cord blood transplant with busulfan-based myeloablative conditioning at the University of Minnesota Masonic Children's Hospital was used prospectively since 2017. The primary endpoint was CD4

resultsA total of 27 patients were included in the study. Median follow-up time was 31 months (interquartile range [IQR], 22-38) and median age was 1.5 years (IQR, 0.7-3.9). The underlying disease was Hurler syndrome in 17 (63%), Hunter syndrome in 4 (15%), and cerebral adrenoleukodystrophy in 4 (15%) patients; 2 patients were transplanted for other IEM. The CD4

conclusionIn patients with IEM, individualized dosing of rATG was associated with a robust and early CD4

Indexed as

Antilymphocyte SerumBody WeightCD4-Positive T-LymphocytesCord Blood Stem Cell TransplantationImmune ReconstitutionMetabolism, Inborn ErrorsAdolescentAnimalsChildChild, PreschoolFemaleGraft vs Host DiseaseHumansInfantLymphocyte CountMaleAntilymphocyte SerumImmune reconstitutionInborn errors of metabolismNomogramRabbit anti-thymocyte globulinUmbilical cord blood transplant

Identifiers

PMID39914492
PMCPMC12581114

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.